lianbio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in china and major asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. lianbio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.
Company profile
Ticker
LIANY
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
LianBio Development (Cayman) Limited • LianBio, LLC • LianBio Development (HK) Limited • LianBio Licensing, LLC • Lian Oncology Limited • Lian Cardiovascular Limited • LianBio Respiratory Limited • LianBio Ophthalmology Limited • LianBio Inflammatory Limited • Shanghai LianBio Development Co., Ltd. ...
LIANY stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
21 Mar 24
EFFECT
Notice of effectiveness
13 Mar 24
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
12 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 24
POS AM
Prospectus update (post-effective amendment)
12 Mar 24
25
Voluntary exchange delisting
11 Mar 24
8-K
LianBio Announces Completion of Strategic Review
13 Feb 24
8-K
Entry into a Material Definitive Agreement
26 Dec 23
Latest ownership filings
4
Ehong Gu
11 Apr 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
29 Feb 24
4
Konstantin Poukalov
20 Feb 24
4
JOSEPH EDELMAN
20 Feb 24
4
Adam Leo Stone
20 Feb 24
4
ANASTASIOS GIANAKAKOS
20 Feb 24
4
Susan Michele Silbermann
20 Feb 24
144
Notice of proposed sale of securities
8 Jan 24
144
Notice of proposed sale of securities
29 Dec 23
3
Ehong Gu
26 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 103.53 mm | 103.53 mm | 103.53 mm | 103.53 mm | 103.53 mm | 103.53 mm |
Cash burn (monthly) | 200.67 k | (no burn) | 8.77 mm | 8.88 mm | 5.29 mm | 6.96 mm |
Cash used (since last report) | 1.37 mm | n/a | 59.73 mm | 60.50 mm | 36.03 mm | 47.43 mm |
Cash remaining | 102.16 mm | n/a | 43.79 mm | 43.02 mm | 67.50 mm | 56.10 mm |
Runway (months of cash) | 509.1 | n/a | 5.0 | 4.8 | 12.8 | 8.1 |
Institutional ownership, Q3 2023
77.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 39 |
Opened positions | 6 |
Closed positions | 7 |
Increased positions | 8 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 111.65 bn |
Total shares | 83.80 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Perceptive Advisors | 57.56 mm | $85.76 bn |
Venrock Healthcare Capital Partners II | 4.79 mm | $0.00 |
Viking Global Investors | 3.56 mm | $5.31 bn |
Tybourne Capital Management | 3.30 mm | $4.92 bn |
T. Rowe Price | 2.60 mm | $3.87 mm |
Vida Ventures Advisors | 2.28 mm | $3.40 bn |
22NW | 2.21 mm | $3.30 bn |
Tang Capital Management | 1.80 mm | $2.68 bn |
SCHF (gpe) | 937.50 k | $1.40 mm |
Affinity Asset Advisors | 672.36 k | $1.00 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Apr 24 | Ehong Gu | Ordinary Shares | Sale back to company | Dispose D | No | No | 0.32 | 17,889 | 5.72 k | 0 |
2 Jan 24 | Ehong Gu | Ordinary Shares | Sell | Dispose S | No | No | 4.34 | 1,731 | 7.51 k | 76,762 |
21 Jun 23 | Stone Adam Leo | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 2.4 | 36,300 | 87.12 k | 36,300 |
21 Jun 23 | Poukalov Konstantin | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 2.4 | 36,300 | 87.12 k | 36,300 |
21 Jun 23 | Perceptive Advisors | Stock Option Ordinary Shares | Grant | Acquire A | Yes | No | 2.4 | 36,300 | 87.12 k | 36,300 |
21 Jun 23 | Perceptive Advisors | Stock Option Ordinary Shares | Grant | Acquire A | Yes | No | 2.4 | 36,300 | 87.12 k | 36,300 |
News
What's Going On With LianBio (LIAN) Stock?
15 Mar 24
LianBio Reports Voluntarily Delisting From Nasdaq;
28 Feb 24
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
13 Feb 24
Ecolab Posts Strong Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Tuesday
13 Feb 24